Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.02 USD | -1.23% | +4.69% | +648.60% |
May. 31 | Piper Sandler Starts Elevation Oncology With Overweight Rating, $10 Price Target | MT |
May. 14 | Stephens Starts Elevation Oncology With Overweight Rating, $8 Price Target | MT |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 220M |
---|---|---|---|---|---|
Net income 2024 * | -48M | Net income 2025 * | -60M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-4.33
x | P/E ratio 2025 * |
-4.36
x | Employees | 29 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 94.73% |
1 day | -1.23% | ||
1 week | +4.69% | ||
1 month | +0.50% | ||
3 months | -19.76% | ||
6 months | +688.24% | ||
Current year | +648.60% |
Managers | Title | Age | Since |
---|---|---|---|
Joseph Ferra
CEO | Chief Executive Officer | 48 | 21-06-16 |
Tammy Furlong
DFI | Director of Finance/CFO | 53 | - |
Steven Elms
CHM | Chairman | 60 | 19-04-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
R. Carruthers
BRD | Director/Board Member | 66 | 21-05-17 |
Timothy Clackson
BRD | Director/Board Member | 58 | 20-04-30 |
Steven Elms
CHM | Chairman | 60 | 19-04-30 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-31 | 4.02 | -1.23% | 397,720 |
24-05-30 | 4.07 | +2.52% | 260,620 |
24-05-29 | 3.97 | +3.66% | 447,826 |
24-05-28 | 3.83 | -0.26% | 613,153 |
24-05-24 | 3.84 | +4.07% | 1,200,303 |
Delayed Quote Nasdaq, May 31, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+648.60% | 220M | |
+11.60% | 106B | |
-4.68% | 24.28B | |
-0.82% | 21.96B | |
-10.12% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+2.77% | 13.63B | |
+34.58% | 12.27B | |
+77.64% | 8.87B |
- Stock Market
- Equities
- ELEV Stock